IMATINIB-CHORDOMA-P2

NCT00150072 📎

Regimen

Experimental
Imatinib 800 mg PO daily continuous (PDGFR/KIT/BCR-ABL tyrosine kinase inhibitor)
Control
none (single-arm)

Population

Advanced PDGFRB-positive unresectable/metastatic chordoma progressing after local therapy; all histologic subtypes allowed

Key finding

Established imatinib as the first systemic therapy with demonstrable activity in chordoma — low RECIST response but meaningful disease stabilization in a disease with no cytotoxic option. Mechanism: PDGFRB pathway inhibition rather than oncogenic addiction.

Source: PMID 22331945

Timeline

    Guideline citations

    • NCCN BONE (p.28)